Publications
196. Platzbecker AS,Georgi JA, Middeke JM, Sockel K, Wehner R, Herbst RT, Wolf D, Baldus CD, Oelschlaegel U, Mütherig A, Fransecky L, Noppeney R, Bug G, Götze KS, Krämer A, Bochtler T, Stelljes M, Esseling E, Stölzel F, von Bonin M, Serve H, Hänel M, Dührsen U, Harig A, Müller-Tidow C, Schetelig J, Stasik S, Röllig C, Ehninger G, Kramer M, Schmitz M, Bornhäuser M, Platzbecker U, Thiede C. Azacitidine to treat measurable residual disease in patients with MDS/AML - final long-term results of the RELAZA2 trial. Blood. In press.
195. Lakshmi K, von Jutrzenka-Trzebiatowski A, Loureiro L, González Soto KE, Peter K, Marín Morales JM, Santosh Nirmala SS, Berndt N, Arndt C, Hu Y, Li JW, Peitzsch C, Taubenberger A, Wehner R, Schmitz M, Hölig K, Abken H, Bonifacio E, Bornhäuser M, Bachmann M, Feldmann A, Fuchs A. Automated GMP-compatible production of universal CAR Tregs for precision immunomodulation. J Transl Med. 2025;23:1399.
194. Prummel KD, Woods K, Kholmatov M, Schmitt EC, Vlachou EP, Labyadh M, Wehner R, Poschmann G, Stühler K, Winter S, Oelschlaegel U, Wobus M, Schwartz LS, Moura PL, Hellström-Lindberg E, Rajalingam K, Theobald M, Trowbridge JJ, Carron C, Jaffredo T, Schmitz M, Platzbecker U, Zaugg JB, Guezguez B. Inflammatory stromal and T cells mediate human bone marrow niche remodeling in clonal hematopoiesis and myelodysplasia. Nat Commun. 2025;16:10042.
193. Rothe R, Tunger A, Link T, Lai X, Kuhlmann JD, Wimberger P, Schmitz M, Wehner R. Multi-compartment immune cell profiling highlights the prognostic relevance of CD127+ CD8+ T cells for patients with high-grade serous ovarian cancer. Front Immunol. 2025;16:1607471.
192. Baenke F, Stammberger A, Sommer U, Brückmann S, Merboth F, Polster H, Digomann D, Natusch L, Rupp L, Aust DE, Weitz J, Stange DE, Schmitz M, Seifert L, Seifert AM. Intratumoural regulatory T cells are associated with treatment response to neoadjuvant chemotherapy and prognosis in gastroesophageal adenocarcinoma. Oncoimmunology. 2025;14:2574859.
191. Digomann D, Reiche C, Stammberger A, Willms T, Rudek LS, Grabenkamp A, Klimova A, Koelbel J, Merboth F, Natusch L, Beer C, Golle T, Cronjaeger S, Hoffmann F, Kranich L, Schmitz M, Bruns CJ, Schlößer HA, Weitz J, Seifert L, Seifert AM. Soluble TIM-3 and galectin-9 predict survival in gastric and gastroesophageal junction cancer. iScience. 2025;28:113871.
190. Fritzsch A, Leucht K, Röber N, Conrad K, Rothe R, Wehner R, Schumacher U, Esteban E, Barthélémy P, Schmidinger M, Schmitz M, Grimm MO. Profiling autoantibodies at baseline and during immune checkpoint inhibitor therapy of renal cell carcinoma patients - exploratory results from TITAN-RCC. ESMO Open. 2025;10:105575.
189. Möhrmann L, Rostock L, Werner M, Oleś M, Arnold JS, Paramasivam N, Jöhrens K, Rupp L, Schmitz M, Richter D, Uhrig S, Fröhlich M, Hutter B, Hüllein J, Jahn A, Arlt M, Möhrmann EE, Hanf D, Gieldon L, Kreutzfeldt S, Heilig CE, Teleanu MV, Lipka DB, Beck K, Baude-Müller A, Mock A, Jelas I, Rieke DT, Wiesweg M, Brandts C, Boerries M, Illert AL, Desuki A, Kindler T, Krackhardt AM, Westphalen CB, Christopoulos P, Apostolidis L, Stenzinger A, Allgäuer M, Neumann O, Kerle IA, Horak P, Heining C, Grosch H, Schröck E, Hübschmann D, Fröhling S, Glimm H. Genomic landscape and molecularly-informed therapy in thymic carcinoma and other advanced thymic epithelial tumors. Med. In press.
188. Rothe R, Golle T, Hachkar B, Hörz T, Pablik J, Rupp L, Dietsche I, Kruppa C, Fitze G, Schmitz M, Haase M, Wehner R. Tertiary lymphoid structures are associated with progression-free survival of peripheral neuroblastic tumor patients. Cancers. 2025;17:1303.
187. Tever O, Mentrup T, Chinn IK, Ishikuma H, Fluhrer R, Schmitz M, Wehner R, Behrendt R, Chinen J, Schröder B. The DNase TREX1 is a substrate of the intramembrane protease SPP with implications for disease pathogenesis. Cell Mol Life Sci. 2025;82:107.
186. Crespo E, Loureiro LR, Stammberger A, Hoffmann L, Berndt N, Hoffmann A, Dagostino C, Soto KEG, Rupp L, Arndt C, Schneider M, Ball CR, Bachmann M, Schmitz M, Feldmann A. RevCAR-mediated T cell response against PD-L1-expressing cells turns suppression into activation. NPJ Precis Oncol. 2025;9:42.
185. Goel M, Steinberg-Bains K, Eugster A, Wehner R, Tunger A, Reinhardt S, Sharma V, Rost F, Schmitz M, Schmelz R, Zeissig S, Rachner TD, Bornhäuser M, Bonifacio E, Link-Rachner CS. Combining T cell receptor sequencing and transcriptomics to characterize tissue-resident T cells from human gut biopsies. Biochem Biophys Res Commun. 2025;749:151353.
184. Messmer JM, Thommek C, Piechutta M, Venkataramani V, Wehner R, Westphal D, Schubert M, Mayer CD, Effern M, Berghoff AS, Hinze D, Helfrich I, Schadendorf D, Wick W, Hölzel M, Karreman MA, Winkler, F. T lymphocyte recruitment to melanoma brain tumors depends on distinct venous vessels. Immunity. In press.
183. Priego N, de Pablos-Aragoneses A, Perea-García M, Pieri V, Hernández-Oliver C, Álvaro-Espinosa L, Rojas A, Sánchez O, Steindl A, Caleiras E, García F, García-Martín S, Graña-Castro O, García-Mulero S, Serrano D, Velasco-Beltrán P, Jiménez-Lasheras B, Egia-Mendikute L, Rupp L, Stammberger A, Meinhardt M, Chaachou A, Martínez-Saez E, Bertero L, Cassoni P, Mangherini L, Pellerino A, Rudà R, Soffietti R, Al-Shahrour F, Saftig P, Sanz-Pamplona R, Schmitz M, Crocker SJ, Calvo A, Palazón A, RENACER23, Valiente M. TIMP1 mediates astrocyte-dependent local immunosuppression in brain metastasis acting on infiltrating CD8+ T cells. Cancer Discov. In press.
182. Salek M, Förster JD, Becker JP, Meyer M, Charoentong P, Lyu Y, Lindner K, Lotsch C, Volkmar M, Momburg F, Poschke I, Fröhling F, Schmitz M, Offringa R, Platten M, Jäger D, Zörnig I, Riemer AB. optiPRM: A targeted immunopeptidomics LC-MS workflow with ultra-high sensitivity for the detection of mutation-derived tumor neoepitopes from limited input material. Mol Cell Proteomics. In press.
181. Helbig K, Towers R, Schmitz M, Bornhäuser M, Lennig P, Zhang Y. Cyclosporin A-based PROTACs can deplete abundant cellular cyclophilin A without influencing T-cell proliferation and cytokine production. Molecules. 2024;29:2779.
180. Kirchner J, Plesca I, Rothe R, Resag A, Löck S, Benešová I, Rupp L, Linge A, Wehner R, Krause M, Schmitz M. Type I conventional dendritic cells and CD8+ T cells predict favorable clinical outcome of head and neck squamous cell carcinoma patients. Front Immunol. 2024;15:1414298.
179. Igbo BT, Jentsch C, Linge A, Plesca I, Kuzay Y, Löck S, Kumaravadivel MS, Doms S, Stolz-Kieslich L, Pollack D, Brückmann S, Tittlbach H, Weitz J, Aust D, Apolle R, Schmitz M, Troost EGC. Correlation of microscopic tumor extension with tumor microenvironment in esophageal cancer patients. Strahlenther Onkol. 2024;200:595-604.
178. Grimm MO, Schostak M, Grün CB, Loidl W, Pichler M, Zimmermann U, Schmitz-Dräger B, Steiner T, Roghmann F, Niegisch G, Bolenz C, Schmitz M, Baretton G, Leucht K, Schumacher U, Foller S, Zengerling F, Meran J. Nivolumab + ipilimumab as immunotherapeutic boost in metastatic urothelial carcinoma: A nonrandomized clinical trial. JAMA Oncol. 2024;10:755-764
177. Winter S, Schneider M, Oelschlaegel U, Maggioni G, Riva E, Raddi MG, Bencini S, Peruzzi B, Choy D, Antunes Dos Reis R, Güse E, Lischer C, Vera J, Timms JA, Sompairac N, Sockel K, Poloni A, Tunger A, Della Porta MG, Santini V, Schmitz M, Platzbecker U, Kordasti S. Mutations in the splicing factor SF3B1 are linked to frequent emergence of HLA-DR low/neg monocytes in lower-risk myelodysplastic neoplasms. Leukemia. 2024;38:1127-1131.
176. Winter S, Götze KS, Hecker JS, Metzeler KH, Guezguez B, Woods K, Medyouf H, Schäffer A, Schmitz M, Wehner R, Glauche I, Roeder I, Rauner M, Hofbauer LC, Platzbecker U. Clonal hematopoiesis and its impact on the aging osteo-hematopoietic niche. Leukemia. 2024;38:936-946.
175. Rupp L, Dietsche I, Kiessler M, Sommer U, Muckenhuber A, Steiger K, Van Eijck CWF, Richter L, Istvanffy R, Jäger C, Friess H, Van Eijck CHJ, Demir IE, Mota Reyes C, Schmitz M. Neoadjuvant chemotherapy is associated with suppression of the B cell-centered landscape in pancreatic ductal adenocarcinoma. Front Immunol. 2024;15: 1378190.
174. Hornsteiner F, Vierthaler J, Strandt H, Resag A, Fu Z, Ausserhofer M, Tripp CH, Dieckmann S, Kanduth M, Farrand K, Bregar S, Nemati N, Hermann-Kleiter N, Seretis A, Mullins DW, Finotello F, Trajanoski Z, Wollmann G, Ronchese F, Schmitz M, Hermans IF, Stoitzner P. Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma. J Immunother Cancer. 2024;12:e008606.
173. Ibneeva L, Singh SP, Sinha A, Eski SE, Wehner R, Rupp L, Kovtun I, Pérez-Valencia JA, Gerbaulet A, Reinhardt S, Wobus M, von Bonin M, Sancho J, Lund F, Dahl A, Schmitz M, Bornhäuser M, Chavakis C, Wielockx B, Grinenko T. CD38 promotes hematopoietic stem cell dormancy. PLoS Biol. 2024;22:e3002517.
172. Towers R, Trombello L, Fusenig M, Tunger A, Baumann AL, Savoldelli R, Wehner R, Fasslrinner F, Arndt C, Dazzi F, Von Bonin M, Feldmann F, Bachmann MP, Wobus M, Schmitz M, Bornhäuser M. Bone marrow-derived mesenchymal stromal cells obstruct AML-targeting CD8+ clonal effector and CAR T cell function while promoting a senescence-associated phenotype. Cancer Immunol Immunother. 2024;73:8.
171. Dinter L, Karitzky PC, Schulz A, Wurm A, Mehnert MC, Sergon M, Tunger A, Lesche M, Wehner R, Müller A, Käubler T, Niessner H, Dahl A, Beissert S, Schmitz M, Meier F, Seliger B, Westphal D. BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS-mutant melanoma cells: Insights into mode of action and resistance mechanisms. Int J Cancer. 2024;154:1057-1072.
170. Loureiro LR, Hoffmann L, Neuber C, Rupp L, Arndt C, Kegler A, Kubeil M, Hagemeyer CE, Stephan H, Schmitz M, Feldmann A, Bachmann M. Immunotheranostic target modules for imaging and navigation of UniCAR T-cells to strike FAP-expressing cells and the tumor microenvironment. J Exp Clin Cancer Res. 2023;42:341.
169. Grimm MO, Esteban E, Barthélémy P, Schmidinger M, Busch J, Valderrama BP, Charnley N, Schmitz M, Schumacher U, Leucht K, Foller S, Baretton G, Duran I, de Velasco G, Priou F, Maroto P, Albiges L. Tailored Approach with nivolumab and nivolumab/ipilimumab as immunotherapeutic boost in metastatic renal cell carcinoma. Lancet Oncol. 2023;24:1252-1265.
168. Nelde A, Schuster H, Heitmann JS, Bauer J, Mariner Y, Zwick M, Volkmer JP, Chen JY, Paczulla Stanger AM, Lehmann A, Appiah B, Märklin M, Rücker-Braun E, Salih HR, Roerden M, Schroeder SM, Häring MF, Schlosser A, Schetelig J, Schmitz M, Boerries M, Köhler N, Lengerke C, Majeti R, Weissmann IL, Rammensee HG, Walz JS. Immune surveillance of acute myeloid leukemia is mediated by HLA-presented antigens on leukemia progenitor cells. Blood Cancer Discov. 2023;4:468-489.
167. Rupp L, Resag A, Potkrajcic V, Warm V, Wehner R, Jöhrens K, Bösmüller H, Eckert F, Schmitz M. Prognostic impact of the post-teatment T cell composition and spatial organization in soft tissue sarcoma patients treated with neoadjuvant hyperthermic radio(chemo)therapy. Front Immunol. 2023;14:1185197.
166. Digomann D, Strack J, Heiduk M, Plesca I, Rupp L, Reiche C, Nikolaus S, Beer C, Sommer U, Schmitz M, Distler M, Weitz J, Seifert AM, Seifert L. VISTA ligation reduces anti-tumor T cell activity in pancreatic cancer. Cancers. 2023;15:2326.
165. Grimm MO, Grün CB, Niegisch G, Pichler M, Roghmann F, Schmitz-Dräger B, Baretton G, Schmitz M, Bolenz C, Foller S, Leucht K, Schumacher U, Schostak M, Meran J, Loidl W, Zengerling F. Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single arm, phase 2 trial. Lancet Oncol. 2023;24:347-359.
164. Bayerl F, Bejarano DA, Bertacchi G, Doffin AC, Gobbini E, Hubert M, Li L, Meiser P, Pedde AM, Posch W, Rupp L, Schlitzer A, Schmitz M, Schraml B, Uderhardt S, Valladeau-Guilemond J, Wilflingseder D, Zaderer V, Böttcher JP. Guidelines for visualization and analysis of DC in tissues using multiparameter fluorescence microscopy imaging methods. Eur J Immunol. 2023;51:e2249923.
163. Arndt C, Tunger A, Wehner R, Rothe R, Kourtellari E, Luttosch S, Hannemann K, Koristka S, Loureiro LR , Feldmann A, Tonn T, Link T, Kuhlmann JD, Wimberger P, Bachmann MP, Schmitz M. Palbociclib impairs the proliferative capacity of activated T cells while retaining their cytotoxic efficacy. Front Pharmacol. 2023;14:970457.
162. Schumann T, Costas Ramon S, Schubert N, Mayo MA, Hega M, Maser KI, Ada SR, Sydow L, Hajikazemi M, Badstübner M, Müller P, Ge Y, Shakeri F, Buness A, Rupf B, Linienklaus S, Utess B, Muhandes L, Haase M, Rupp L, Schmitz M, Gramberg T, Manel N, Hartmann G, Zillinger T, Kato H, Bauer S, Gerbaulet A, Paeschke K, Roers A, Behrendt R. Deficiency for SAMHD1 activates MDA5 in a GAS/STING-dependent manner. J Exp Med. 2023;220:e20220829.
161. Walther R, Wehner R, Tunger A, Julius U, Schatz U, Tselmin S, Bornstein SR, Schmitz M, Graessler J. Repeated lipoprotein apheresis and immune response: Effects on different immune cell populations. Ther Apher Dial. 2022;Suppl 1:18-28.
160. Heiduk M, Plesca I, Glück J, Müller L, Digomann D, Reiche C, von Renesse J, Decker R, Kahlert C, Sommer U, Aust DE, Schmitz M, Weitz J, Seifert L, Seifert AM. Neoadjuvant chemotherapy drived intratumoral T cells towards a pro-inflammatory profile in pancreatic cancer. JCI Insight. 2022;7:e152761.
159. Krüger T, Wehner R, Herbig M, Kräter M, Kramer M, Middeke JM, Stölzel F, List C, Egger-Heidrich K, Teipel R, Oelschlägel U, Wermke M, Jambor H, Wobus M, Schetelig J, Jöhrens K, Tonn T, Subburayalu J, Schmitz M, Bornhäuser M, von Bonin M. Perturbations of mesenchymal stromal cells after allogeneic hematopoietic cell transplantation predispose for bone marrow graft-versus-host-disease. Front Immunol. 2022;13:1005554.
158. Resag A, Toffanin G, Benesova I, Müller L, Potkrajcic V, Ozaniak A, Lischke R, Bartunkova J, Rosato A, Jöhrens K, Eckert F, Strizova Z, Schmitz M. The immune contexture of liposarcoma and its clinical implications. Cancers. 2022;14:4578.
157. Schubert N, Schumann T, Daum E, Flade K, Ge Y, Hagedorn L, Edelmann W, Müller L, Schmitz M, Kuut G, Hornung V, Behrendt R, Roers A. Genome replication is associated with release of immunogeneic DNA waste. Front Immunol. 2022;13:880413.
156. Grimm, MO, Schmitz-Dräger BJ, Zimmermann U, Grün CB, Baretton GB, Schmitz M, Foller S, Leucht K, Schostak M, Zengerling F, Schumacher U, Loidl W, Meran J. Tailored Immunotherapy Approach with Nivolumab in advanced transitional cell carcinoma (TITAN-TCC). J Clin Oncol. 2022;40:2128-2137.
155. Plesca I, Müller L, Böttcher JP, Medyouf H, Wehner R, Schmitz M. Tumor-associated human dendritic cell subsets: phenotype, functional orientation, and clinical relevance. Eur J Immunol. 2022;52:1750-1758.
154. Peuker K, Strigli A, Tauriello DVF, Hendricks A, von Schönfels W, Burmeister G, Brosch M, Herrmann A, Krüger S, Nitsche J, Južnić L, Geissler MM, Hiergeist A, Gessner A, Wirbel J, Priyadarshini Ponnudurai R, Voogdt CGP, Tunger A, Wehner R, Stange DE, Weitz J, Aust DE, Baretton GB, Schmitz M, Röcken C, Hampe J, Hinz S, Zeller G, Chavakis T, Schafmayer C, Batlle E, Zeissig. Microbiota-dependent activation of the myeloid calcineurin-NFAT pathway inhibits B7H3- and B7H4-dependent anti-tumor immunity in colorectal cancer. Immunity. 2022;55:701-717.
153. Mentrup T, Stumpff-Niggemann AY, Leinung N, Schlosser C, Schubert K, Wehner R, Tunger A, Schatz V, Neubert P, Gradtke AC, Wolf J, Rose-John S, Saftig P, Dalpke A, Jantsch J, Schmitz M, Fluhrer R, Jacobsen ID, Schröder B. Phagosomal signalling of the C-type lectin receptor Dectin-1 is terminated by intramembrane proteolysis. Nat Commun. 2022;13:1880.
152. Plesca I, Benešová I, Beer C, Sommer U, Müller L, Wehner R, Heiduk M, Aust D, Baretton G, Bachmann MP, Feldmann A, Weitz J, Seifert L, Seifert AM, Schmitz M. Clinical significance of tumor-infiltrating conventional and plasmacytoid dendritic cells in pancreatic ductal adenocarcinoma. Cancers. 2022;14:1216.
151. Augsberger C, Hänel G, Xu W, Pulko V, Hanisch LJ, Augustin A, Challier J, Hunt K, Vick B, Rovatti PE, Krupka C, Rothe M, Schönle A, Sam J, Lezan E, Ducret A, Ortiz-Franyuti D, Walz AC, Benz J, Bujotzek A, Lichtenegger FS, Gassner C, Carpy A, Lyamichev V, Patel J, Konstandin NP, Tunger A, Schmitz M, von Bergwelt-Baildon M, Spiekermann K, Vago L, Jeremias I, Marrer-Berger E, Umana P, Klein C, Subklewe M. Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC specific T cell bispecific antibody. Blood. 2021;138:2655-2669.
150. Nathansen J, Meyer F, Müller L, Schmitz M, Borgmann K, Dubrovska A. Beyond The Double-strand Breaks: The Role of DNA Repair Proteins in Cancer Stem Cell Regulation. Cancers. 2021;13:4818.
149. Berndt N, Bippes CC, Michalk I, Bartsch T, Arndt C, Puentes-Cala E, Soto JA, Loureiro LR, Kegler A, Bachmann D, Gross JK, Gross T, Kurien BT, Scofield RH, Farris AD, James JA, Bergmann R, Schmitz M, Feldmann A, Bachmann MP. And yet it moves: Oxidation of the nuclear autoantigen La/SS-B is the driving force for nucleo-cytoplasmic shuttling. Int J Mol Sci. 2021;22:9699.
148. Branchi V, Esser L, Boden C, Jafari A, Henn J, Lingohr P, Gonzalez-Carmona M, Schmitz M, Weismüller TJ, Strassburg CP, Manekeller S, Kristiansen G, Kalff JC, Matthaei H, Toma MI. A combined TLR7/TLR9/GATA3 score can predict prognosis in biliary tract cancer. Diagnostics. 2021;11:1597.
147. Tirado-Gonzalez I, Descot A, Soetopo D, Nevmerzhitskaya A, Schäffer A, Kur IM, Czlonka E, Wachtel C, Tsoukala I, Müller L, Schäfer AL, Weitmann M, Dinse P, Alberto E, Buck MC, Landry JJM, Baying B, Slotta-Huspenina J, Roesler J, Harter PN, Kubasch AS, Meinel J, Elwakeel E, Strack E, Tran Quang C, Abdel-Wahab O, Schmitz M, Weigert A, Schmid T, Platzbecker U, Benes V, Ghysdael J, Bonig H, Götze KS, Rothlin CV, Ghosh S, Medhouf H. AXL inhibition in macrophages stimulates host-versus-leukemia immunity and eradicates naïve and treatment resistant leukemia. Cancer Discov. 2021;11:2924-2943.
146. Kießler M, Plesca I, Sommer U, Wehner R, Wilczkowski F, Müller L, Tunger A, Lai X, Rentsch A, Peuker K, Zeissig S, Seifert AM, Seifert L, Weitz J, Bachmann M, Bornhäuser M, Aust D, Baretton G, Schmitz M. Tumor-infiltrating plasmacytoid dendritic cells are associated with survival in human colon cancer. J Immunother Cancer. 2021;9:e001813.
145. Seifert L, Plesca I, Müller L, Sommer U, Heiduk M, von Renesse J, Digomann D, Glück J, Klimova A, Weitz J, Schmitz M, Seifert AM. LAG-3-Expressing Tumor-Infiltrating T Cells Are Associated with Reduced Disease-Free Survival in Pancreatic Cancer. Cancers. 2021;13:1297.
144. Berndt N, Bippes CC, Michalk I, Bachmann D, Bachmann J, Puentes-Cala E, Bartsch T, Loureiro LR, Kegler A, Bergmann R, Gross JK, Gross T, Kurien BT, Scofield RH, Farris AD, James JA, Schmitz M, Fahmy K, Feldmann A, Arndt C, Bachmann MP. Two Be or Not Two Be: The Nuclear Autoantigen La/SS-B Is Able to Form Dimers and Oligomers in a Redox Dependent Manner. Int J Mol Sci. 2021;22:3377.
143. Müller L, Tunger A, Wobus M, von Bonin M, Towers R, Bornhäuser M, Dazzi F, Wehner R, Schmitz M. Immunomodulatory Properties of Mesenchymal Stromal Cells: An Update. Front Cell Dev Biol. 2021;9:637725.
142. Bachmann MP, Bartsch T, Bippes CC, Bachmann D, Puentes-Cala E, Bachmann J, Bartsch H, Arndt C, Koristka S, Loureiro LR, Kegler A, Laube M, Gross JK, Gross T, Kurien BT, Scofield RH, Farris AD, James JA, Schmitz M, Feldmann A. T Cell Mediated Conversion of a Non-Anti-La Reactive B Cell to an Autoreactive Anti-La B Cell by Somatic Hypermutation. Int J Mol Sci. 2021;22:1198.
141. Seifert AM, Eymer A, Heiduk M, Wehner R, Tunger A, Renesse J, Decker R, Aust DE, Welsch T, Reissfelder C, Weitz J, Schmitz M, Seifert L. PD-1 Expression by Lymph Node and Intratumoral Regulatory T Cells Is Associated with Lymph Node Metastasis in Pancreatic Cancer. Cancers. 2020;12:E2756.
140. Pearson FE, Tullett KM, Leal-Rojas IM, Haigh OL, Masterman KA, Walpole C, Bridgeman JS, McLaren JE, Ladell K, Miners K, Llewellyn-Lacey S, Price DA, Tunger A, Schmitz M, Miles JJ, Lahoud MH, Radford KJ. Human CLEC9A Antibodies Deliver Wilms' Tumor 1 (WT1) Antigen to CD141 + Dendritic Cells to Activate naïve and Memory WT1-specific CD8 + T Cells. Clin Transl Immunology. 2020;9:e1141
139. Vadakekolathu J, Minden MD, Hood T, Church SE, Reeder S, Altmann H, Sullivan AH, Viboch EJ, Patel T, Ibrahimova N, Warren SE, Arruda A, Liang Y, Smith TH, Foulds GA, Bailey MD, Gowen-MacDonald J, Muth J, Schmitz M, Cesano A, Pockley AG, Valk PJM, Löwenberg B, Bornhäuser M, Tasian SK, Rettig MP, Davidson-Moncada JK, DiPersio JF, Rutella S. Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia. Sci Transl Med. 2020;12:eaaz0463.
138. Plesca I, Tunger A, Müller L, Wehner R, Lai X, Grimm MO, Rutella S, Bachmann M, Schmitz M. Characteristics of tumor-infiltrating lymphocytes prior to and
during immune checkpoint inhibitor therapy. Front Immunol. 2020;11:364.
137. Binnewerg B, Schubert M, Voronkina A, Muzychka L, Wysokowski M, Petrenko I, Djurovic M, Kovalchuk V, Tsurkan M, Martinovic R, Bechmann N, Fursov A, Ivanenko VN, Tabachnick KR, Smolii OB, Joseph Y, Giovine M, Bornstein SR, Stelling AL, Tunger A, Schmitz M, Taniya OS, Kovalev IS, Zyryanov GV, Guan K, Ehrlich H. Marine biomaterials: Biometric and pharmacological potential of cultivated Aplysina aerophoba marine demosponge. Mater Sci Eng C Mater Biol Appl. 2020;109:110566.
136. Müller L, Tunger A, Plesca I, Wehner R, Temme A, Westphal D, Meier F, Bachmann M, Schmitz M. Bidirectional crosstalk between cancer stem cells and immune cell subsets. Front Immunol. 2020;11:140.
135. Arndt C, Loureiro LR, Feldmann A, Jureczek J, Bergmann R, Mathe D, Hegedüs N, Berndt N, Koristka S, Mitwasi N, Fasslrinner F, Lamprecht C, Kegler A, Hoffmann A, Bartsch T, Köseer AS, Egan G, Schmitz M, Horejsi V, Krause M, Dubrovska A, Bachmann M. UniCAR T cell immunotherapy enables efficient elimination of radioresistant cancer cells. Oncoimmunology. 2020;9:1743036.
134. Mitwasi N, Feldmann A, Arndt C, Koristka S, Berndt N, Jureczek J, Loureiro LR, Bergmann R, Mathe D, Hegedüs N, Kovacs T, Zhang C, Oberoi P, Jäger E, Seliger B, Rössig C, Temme A, Eitler J, Tonn T, Schmitz M, Hassel JC, Jäger D, Wels WS, Bachmann M. “UniCAR”-modified off-the-shelf NK-92 cells for targeting to GD2-expressing tumour cells. Sci Rep. 2020;10:2141.
133. Gellrich FF, Schmitz M, Beissert S, Meier F. Anti-PD-1 and novel combinations in the treatment of melanoma – An update. J Clin Med. 2020,9:E223.
132. Krüger T, Middeke JM, Stölzel F, Mütherig A, List C, Brandt K, Heidrich K, Teipel R, Ordemann R, Schuler U, Oelschlägel U, Wermke W, Kräter M, Herbig M, Wehner R, Schmitz M, Bornhäuser M, von Bonin M. Reliable isolation of human mesenchymal stromal cells from bone marrow biopsies in patients after allogeneic hematopoietic cell transplantation. Cytotherapy. 2020;22:21-26.
131. Rammensee HG, Wiesmüller KH, Chandran PA, Zelba H, Rusch E, Gouttefangeas C, Kowalewski DJ, Di Marco M, Haen SP, Walz JS, Gloria YC, Bödder J, Schertel JM, Tunger A, Müller L, Kießler M, Wehner R, Schmitz M, Jakobi M, Schneiderhan-Marra N, Klein R, Laske K, Artzner K, Backert L, Schuster H, Schwenck J, Weber ANR, Pichler BJ, Kneilling M, la Fougère C, Forchhammer S, Metzler G, Bauer J, Weide B, Schippert W, Stevanović S, Löffler MW. A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer. J Immunother Cancer. 2019;7:307.
130. Tunger A, Sommer U, Wehner R, Kubasch AS, Grimm MO, Bachmann MP, Platzbecker U, Bornhäuser M, Baretton G, Schmitz M. The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy. J Clin Med. 2019;8:pii: E1534.
129. Arndt C, Feldmann A, Koristka S, Schäfer M, Bergmann R, Mitwasi N, Berndt N, Bachmann D, Kegler A, Schmitz M, Puentes-Cala E, Soto JA, Ehninger G, Pietzsch J, Liolios C, Wunderlich G, Kotzerke J, Kopka K, Bachmann M. A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR. Oncoimmunology. 2019;8:1659095.
128. Kegler A, Koristka S, Bergmann R, Berndt N, Arndt C, Feldmann A, Hoffmann A, Bornhäuser M, Schmitz M, Bachmann MP. T cells engrafted with a UniCAR 28/z outperform UniCAR BB/z-transduced T cells in the face of regulatory T cell-mediated immunosuppression. Oncoimmunology. 2019;8:e1621676.
127. Ahmad F, Döbel T, Schmitz M, Schäkel K. Current Concepts on 6-sulfo LacNAc Expressing Monocytes (slanMo). Front Immunol. 2019; 10:948.
126. Fasslrinner F, Arndt C, Koristka S, Feldmann A, Altmann H, von Bonin M, Schmitz M, Bornhäuser M, Bachmann M. Midostaurin abrogates CD33-directed UniCAR and CD33-CD3 bispecific antibody therapy in acute myeloid leukaemia. Br J Haematol. 2019; 186:735-740.
125. Adhikaree J, Franks HA, Televantos C, Vaghela P, Kaur AP, Walker D, Schmitz M, Jackson AM, Patel PM. Impaired circulating myeloid CD1c+ dendritic cell function in human glioblastoma is restored by p38 inhibition - implications for the next generation of DC vaccines. Oncoimmunology. 2019;8:1593803.
124. Tietze S, Kräter M, Jacobi A, Taubenberger A, Herbig M, Wehner R, Schmitz M, Otto O, List C, Kaya B, Wobus M, Bornhäuser M, Guck J. Spheroid Culture of Mesenchymal Stromal Cells Results in Morphorheological Properties Appropriate for Improved Microcirculation. Adv Sci. 2019;6:1802104.
123. Wagner F, Hölig U, Wilczkowski F, Plesca I, Sommer U, Wehner R, Kießler M, Jarosch A, Flecke K, Arsova M, Tunger A, Bogner A, Reißfelder C, Weitz J, Schäkel K, Troost EGC, Krause M, Folprecht G, Bornhäuser M, Bachmann MP , Aust D, Baretton G, Schmitz M. Neoadjuvant Radiochemotherapy Significantly Alters the Phenotype of Plasmacytoid Dendritic Cells and 6-Sulfo LacNAc+ Monocytes in Rectal Cancer. Front Immunol. 2019;10:602.
122. Kuske M, Westphal D, Wehner R, Schmitz M, Beissert S, Praetorius C, Meier F. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy. Pharmacol Res. 2018;136:151-159.
121. Olaru F, Döbel T, Lonsdorf AS, Oehrl S, Maas M, Enk AH, Schmitz M, Gröne EF, Gröne HJ, Schäkel K. Intracapillary immune complexes recruit and activate slan-expressing CD16+ monocytes in human lupus nephritis. JCI Insight. 2018; 3:pii: 96492.
120. Matko S, Manderla J, Bonsack M, Schmitz M, Bornhauser, Tonn T, Odendahl M. PRAME peptide-specific CD8+ T cells represent the predominant response against leukemia-associated antigens in healthy individuals. Eur J Immunol. 2018; 48:1400-1411.
119. Baran W, Oehrl S, Ahmad F, Döbel T, Alt C, Buske-Kirschbaum A, Schmitz M, Schäkel K. Phenotype, Function, and Mobilization of 6-Sulfo LacNAc-Expressing Monocytes in Atopic Dermatitis. Front Immunol. 2018;9:1352.
118. Kubasch AS, Wehner R, Bazzurri S, Tunger A, Stasik S, Garzarolli M, Meinel J, Baretton G, Meier F, Thiede C, Schmitz M, Platzbecker U. Clinical, molecular, and immunological responses to pembrolizumab treatment of synchronous melanoma and acute myeloid leukemia. Blood Adv. 2018;2:1187-1190.
117. Koristka S, Kegler A, Bergmann R, Arndt C, Feldmann A, Albert S, Cartellieri M, Ehninger A, Ehninger G, Middeke JM, Bornhäuser M, Schmitz M, Pietzsch J, Akgün K, Ziemssen T, Steinbach J, Bachmann MP. Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology. J Autoimmun. 2018;90:116-131.
116. Albert S, Arndt C, Koristka S, Berndt N, Bergmann R, Feldmann A, Schmitz M, Pietzsch J, Steinbach J, Bachmann M. From mono- to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro and in vivo. Oncotarget. 2018; 9:25597-25616.
115. Tunger A, Kießler M, Wehner R, Temme A, Meier F, Bachmann M, Schmitz M. Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment. Biomedicines. 2018;6:pii: E26.
114. Heidenreich F, Rücker-Braun E, Walz JS, Eugster A, Kühn D, Dietz S, Nelde A, Tunger A, Wehner R, Link CS, Middeke JM, Stölzel F, Tonn T, Stevanovic S, Rammensee HG, Bonifacio E, Bachmann M, Zeis M, Ehninger G, Bornhäuser M, Schetelig J, Schmitz M. Mass spectrometry-based identification of a naturally presented receptor tyrosine kinase-like orphan receptor 1-derived epitope recognized by CD8+ cytotoxic T cells. Haematologica. 2017;102:e460-e464.
113. Oehrl S, Olaru F, Kunze A, Maas M, Pezer S, Schmitz M, Schäkel K. Controlling the pro-inflammatory function of 6-sulfo LacNAc (slan) dendritic cells with dimethylfumarate. J Dermatol Sci. 2017;87:278-284.
112. Matko S, Teichert M, Tunger A, Schmitz M, Bornhäuser M, Tonn T, Odendahl M. Enumeration of WT1-specific CD8+ T cells for clinical application using an MHC Streptamer based no-wash single-platform flow-cytometric assay. Cytometry A. 2017;91:1001-1008.
111. Oehrl S, Prakash H, Ebling A, Trenkler N, Wölbing P, Kunze A, Döbel T, Schmitz M, Enk A, Schäkel K. The phosphodiesterase 4 inhibitor apremilast inhibits Th1 but promotes Th17 responses induced by 6-sulfo LacNAc (slan) dendritic cells. J Dermatol Sci. 2017;87:110-115.
110. Albert S, Arndt C, Feldmann A, Bergmann R, Bachmann D, Koristka S, Ludwig F, Ziller-Walter P, Kegler A, Gärtner S, Schmitz M, Ehninger A, Cartellieri M, Ehninger G, Pietzsch HJ, Pietzsch J, Steinbach J, Bachmann M. A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform. Oncoimmunology. 2017;6:e1287246.
109. Feldmann A, Arndt C, Bergmann R, Loff S, Cartellieri M, Bachmann M, Aliperta R, Hetzenecker M, Ludwig F, Albert S, Ziller-Walter P, Kegler A, Koristka S, Gärtner S, Schmitz M, Ehninger A, Ehninger G, Pietzsch J, Steinbach J, Bachmann M. Retargeting of T lymphocytes to PSCA- or PSMA positive tumors prostate cancer cells using the novel modular chimeric antigen receptor platform technology UniCAR. Oncotarget. 2017;8:31368-31385.
108. Tunger A, Wehner R, von Bonin M, Kühn D, Heidenreich F, Matko S, Nauerth M, Rücker-Braun E, Dietz S, Link CS, Eugster A, Odendahl M, Busch DH, Tonn T, Bonifacio E, Germeroth L, Schetelig J, Bachmann MP, Bornhäuser M, Schmitz M. Generation of high-avidity, WT1-reactive CD8+ cytotoxic T cell clones with anti-leukemic activity by streptamer technology. Leuk Lymphoma. 2017;58:1246-1249.
107. Kunze A, Förster U, Oehrl S, Schmitz M, Schäkel K. Autocrine TNF-a and IL-1b prime 6-sulfo LacNAc+ dendritic cells for high level production of IL-23. Exp Dermatol. 2017;26:314-316.
106. Rücker-Braun E, Schetelig J, Link CS, Schmiedgen M, Tunger A, Vizjak P, Teipel R, Wehner R, Kuehn D, Fuchs YF, Oelschlaegel U, Germeroth L, Schmitz M, Bornhäuser M, Schetelig J, Heidenreich F. Longitudinal analyses of leukemia-associated antigen-specific CD8+ T cells in patients after allogeneic stem cell transplantation. Exp Hematol. 2016;44:1024-1033.
105. Temme A, Schmitz M. Chimeric antigen receptor-engineered primary natural killer cells: a tool to improve adoptive tumor immunotherapy. Immunotherapy. 2016;8:983-986.
104. Link CS, Eugster A, Heidenreich F, Rücker-Braun E, Schmiedgen M, Oelschlägel U, Kühn D, Dietz S, Fuchs Y, Dahl A, de Jesus Domingues AM, Klesse C, Schmitz M, Ehninger G, Bornhäuser M, Schetelig J, Bonifacio E. Abundant CMV reactive clonotypes in the CD8+ T cell receptor alpha repertoire following allogeneic transplantation. Clin Exp Immunol. 2016;184:389-402.
103. Von Dalowski F, Kramer M, Wermke M, Wehner R, Röllig C, Alakel N, Stölzel F, Parmentier S, Sockel K, Krech M, Schmitz M, Platzbecker U, Schetelig J, Bornhäuser M, von Bonin M. Mesenchymal stromal cells for treatment of acute steroid-refractory GvHD: clinical responses and long-term outcome. Stem Cells. 2016;34:357-366.
102. Langosch S, Wehner R, Malecka A, Franks HA, Schäkel K, Bachmann M, Jackson AM, Schmitz M. Impact of p38 mitogen-activated protein kinase inhibition on immunostimulatory properties of human 6-sulfo LacNAc dendritic cells. Immunobiology. 2016;221:166-174.
101. Gouveia de Andrade AV, Bertolino G, Riewaldt J, Bieback K, Karbanova J, Odendahl M, Bornhäuser M, Schmitz M, Corbeil D, Tonn T. Extracellular vesicles secreted by bone marrow- and adipose tissue-derived mesenchymal stroma cells fail to suppress lymphocyte proliferation. Stem Cells Dev. 2015;24:1374-1376.
100. Toma M, Wehner R, Kloß A, Hübner L, Fodelianaki G, Erdmann K, Füssel S, Zastrow S, Meinhardt M, Seliger B, Brech D, Noessner E, Tonn T, Schäkel K, Bornhäuser M, Bachmann MP, Wirth MP, Baretton G, Schmitz M. Accumulation of tolerogenic human 6-sulfo LacNAc dendritic cells in renal cell carcinoma is associated with poor prognosis. Oncoimmunology. 2015;4:e1008342.
99. Müller N, Michen S, Tietze S, Töpfer K, Schulte A, Lamszus K, Schmitz M, Schackert G, Pastan I, Temme A. Engineering NK cells modified with an EGFRvIII-specific chimeric antigen receptor to overexpress CXCR4 improves immunotherapy of CXCL12/SDF-1a-secreting glioblastoma. J Immunother. 2015;38:197-210.
98. Cosgun KN, Rahmig S, Mende N, Reinke S, Hauber I, Schäfer C, Petzold A, Weisbach H, Heidkamp G, Purbojo A, Cesnjevar R, Platz A, Bornhäuser M, Schmitz M, Dudziak D, Hauber J, Kirberg J, Waskow C. Kit regulates HSC engraftment across the human-mouse species barrier. Cell Stem Cell. 2014;15:227-238.
97. Tuve S, Sommer U, Kostka H, Mohr, B, Oelschlägel U, Middecke JM, Berning M, Fantana J, Erler A, Jakob C, Aringer M, Baretton G, Schmitz M, Bornhäuser M, Babatz J. Deletion of 13q14 in plasma cells of a patient with lupus erythematosus and autoimmune hepatitis. J Bone Marrow Res. 2014;2:147.
96. Thomas K, Dietze K, Wehner R, Metz I, Tumani H, Schultheiß T, Günther C, Schäkel K, Reichmann H, Brück W, Schmitz M, Ziemssen T. Accumulation and therapeutic modulation of 6-sulfo LacNAc+ dendritic cells in multiple sclerosis. Neurol Neuroimmunol Neuroinflammation. 2014;1:e33.
95. Odendahl M, Grigoleit GU, Germeroth L, Neuenhahn M, Albrecht J, Anderl F, Bonig H, Schmitz M, Bornhäuser M, Einsele H, Seifried E, Busch DH, Tonn T. Clinical scale isolation of minimally manipulated cytomegalie virus-specific donor lymphocytes for the treatment of refractory cytomegalovirus disease. Cytotherapy. 2014;16:1245-1256.
94. Sommer U, Larsson B, Tuve S, Wehner R, Zimmermann N, Kramer M, Kloß A, Günther C, Babatz J, Schmelz R, Brückner S, Schetelig J, Bornhäuser M, Schäkel K, Bachmann MP, Aust D, Baretton G, and Schmitz M. Proinflammatory human 6-sulfo LacNAc+ dendritic cells accumulate in intestinal acute graft-versus-host disease. Haematologica. 2014;99:e86-e89.
93. Gouveia de Andrade AV, Riewaldt J, Wehner R, Schmitz M, Odendahl M, Bornhäuser M, Tonn T. Gamma irradiation preserves immunosuppressive potential and inhibits clonogenic capacity of human bone marrow-derived mesenchymal stroma cells. J Cell Mol Med. 2014;18:1184-1193.
92. Hauptmann N, Pion M, Wehner R, Munoz-Fernandez MA, Schmitz M, Voit B, Appelhans D. Potential of Ni(II)-NTA modified poly(ethylene imine) gylcopolymers as carrier system for future dendritic cell-based immunotherapy. Biomacromolecules. 2014;15:957-967.
91. Cartellieri M, Arndt C, Feldmann A, von Bonin M, Ewen EM, Koristka S, Michalk I, Stamova S, Berndt N, Gocht A, Bornhäuser M, Ehninger G, Schmitz M, Bachmann M. TCR/CD3 activation and costimulation combined in one T cell targeting system improve anti-tumor immunity. Oncoimmunology. 2013;2:e26770.
90. Arndt C, Feldmann A, von Bonin M, Cartellieri M, Ewen EM, Koristka S, Michalk I, Stamova S, Berndt N, Gocht A, Bornhäuser M, Ehninger G, Schmitz M, Bachmann M. Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: Description of a novel modular targeting system. Leukemia. 2014;28:59-69.
89. Naumann K, Wehner R, Schwarze A, Petzold C, Schmitz M, Rohayem J. Activation of dendritic cells by the novel Toll-like receptor 3 agonist RGC100. Clin Dev Immunol. 2013;2013:283649.
88. Ferrer RA, Wobus M, List C, Wehner R, Schönefeldt C, Brocard B, Mohr B, Rauner M, Schmitz M, Stiehler M, Ehninger G, Hofbauer LC, Bornhäuser M, Platzbecker U. Mesenchymal stromal cells from patients with myelodysplastic syndrome display distinct functional alterations that are modulated by lenalidomide. Haematologica. 2013;98:1677-1698.
87. Wehner R, Taubert C, Mende T, Gaebler C, Gouveia de Andrade AV, Bornhäuser M, Werner C, Tonn T, Schäkel K, Bachmann M, Schmitz M. Engineered extracellular matrix components do not alter the immunomodulatory properties of mesenchymal stromal cells in vitro. J Tissue Eng Regen Med. 2013;7:921-924.
86. Schönefeldt C, Sockel K, Wehner R, Sopper S, Wolf D, Wermke M, Thiede C, Öhlschlägel U, Ehninger G, Bornhäuser M, Platzbecker U, Schmitz M. Azacytidine impairs NK cell activity in AML and MDS patients undergoing MRD-based pre-emptive treatment after allogeneic stem cell transplantation. Blood Cancer J. 2013;3:e136.
85. Döbel T, Kunze A, Babatz J, Tränkner K, Ludwig A, Schmitz M, Enk A, Schäkel K. Fc-gammaRIII equips immature 6-sulfo LacNAc-expressing dendritic cells (slanDCs) with a unique capacity to handle IgG-complexed antigens. Blood. 2013;123:3609-3618.
84. Jähnisch H, Wehner R, Tunger A, Kunze A, Oehrl S, Schäkel K, Rohayem J, Bornhäuser M, Tonn T, Bachmann M, Schmitz M. TLR7/8 agonists trigger immunostimulatory properties of human 6-sulfo LacNAc dendritic cells. Cancer Lett. 2013;1:119-127.
83. Koristka S, Cartellieri M, Arndt C, Bippes CC, Feldmann A, Michalk I, Wiefel K, Stamova S, Schmitz M, Ehninger G, Bornhäuser M, Bachmann M. Retargeting of regulatory T cells to surface-inducible autoantigen La/SS-B. J Autoimmun. 2013; 42:105-116.
82. Arndt C, von Bonin M, Cartellieri M, Feldmann A, Koristka S, Michalk I, Stamova S, Bornhäuser M, Schmitz M, Ehninger G, Bachmann M. Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells. Leukemia. 2013;27:964-967.
81. Bahr F, Wehner R, Platzbecker U, Wermke M, Shayegi N, Middeke JM, Röllig C, Schetelig J, Ehninger G, Schmitz M, Bornhäuser M, Tuve S. Reconstitution of IL-17-producing T helper cells after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013;19:357-365.
80. Hänsel A, Günther C, Baran W, Bidier M, Lorenz HM, Schmitz M, Bachmann M, Döbel T, Enk AH, Schäkel K. Human 6-sulfo LacNAc (slan) dendritic cells have molecular and functional features of an important pro-inflammatory cell type in lupus erythematosus. J Autoimmun. 2013;40:1-8.
79. Wehner R, Bitterlich A, Meyer N, Kloß A, Schäkel K, Bachmann M, Schmitz M. Impact of chemotherapeutic agents on the immunostimulatory properties of human 6-sulfo LacNAc (slan) dendritic cells. Int J Cancer. 2013;132:1351-1359.
78. Faßlrinner F, Wobus M, Duryagina R, Müller K, Stopp S, Wehner R, Rauner M, Hofbauer LC, Schmitz M, Bornhäuser M. Differential effects of mixed lymphocyte reaction supernatant on human mesenchymal stromal cells. Exp Hematol. 2012;40:934-944.
77. Wobus M, Benath G, Ferrer RA, Wehner R, Schmitz M, Hofbauer LC, Rauner M, Ehninger G, Bornhäuser M, Platzbecker U. Impact of lenalidomide on functional properties of human mesenchymal stromal cells. Exp Hematol. 2012;40:867-876.
76. Feldmann A, Arndt C, Töpfer K, Stamova S, Krone F, Cartellieri M, Koristka S, Michalk I, Lindemann D, Schmitz M, Temme A, Bornhäuser M, Ehninger G, Bachmann M. Novel humanized and highly efficient bispecific antibodies for retargeting of T cells to prostate stem cell antigen-expressing tumor cells. J Immunol. 2012;189:3249-3259.
75. Stamova S, Koristka S, Keil J, Arndt C, Feldmann A, Michalk I, Bartsch H, Bippes CC, Schmitz M, Cartellieri M, Bachmann M. Cancer immunotherapy by retargeting of immune effector cells via recombinant bispecific antibody constructs. Antibodies. 2012;1:172-198.
74. Kiessling A, Wehner R, Füssel S, Bachmann M, Wirth MP, Schmitz M. Tumor-associated antigens for specific immunotherapy of prostate cancer. Cancers. 2012;4:193-217.
73. Mager K, Wehner R, Bahr F, Oelschlägel U, Platzbecker U, Wermke M, Shayegi N, Middeke JM, Radke J, Röllig C, Schetelig J, Thiede C, Ehninger G, Schmitz M, Bornhäuser M, Tuve S. Reconstitution of 6-sulfo LacNAc dendritic cells following allogeneic stem cell transplantation. Transplantation. 2012;93:1270-1275.
72. Stamova S, Feldmann A, Cartellieri M, Arndt C, Koristka S, Apel F, Wehner R, Schmitz M, Bornhäuser M, von Bonin M, Ehninger G, Bartsch H, Bachmann M. Generation of single-chain bispecific GFP fusion antibodies for imaging of antibody-induced T cell synapses. Anal Biochem. 2012;423:261-268.
71. Koristka S, Cartellieri M, Theil A, Feldmann A, Arndt C, Stamova S, Michalk I, Töpfer K, Temme A, Kretschmer K, Bornhäuser M, Ehninger G, Schmitz M, Bachmann M. Retargeting of human regulatory T cells by single chain bispecific antibodies. J Immunol. 2012;188:1551-1558.
70. Stamova S, Cartellieri M, Feldmann A, Arndt C, Koristka S, Bippes CC, Wehner R, Schmitz M, von Bonin M, Bornhäuser M, Ehninger G, Bachmann M. Unexpected recombinations in single chain bispecific anti-CD3-antiCD33 antibodies can be avoided by a novel linker molecule. Mol Immunol. 2011;49:474-482.
69. Töpfer K, Kempe S, Müller N, Schmitz M, Bachmann M, Cartellieri M, Schackert G, Temme A. Tumor evasion from T cell surveillance. J Biomed Biotechnol. 2011;2011:918471.
68. Bornhäuser M, Thiede C, Platzbecker U, Kiani A, Oelschlaegel U, Babatz J, Lehmann D, Hölig K, Radke J, Tuve S, Wermke M, Wehner R, Jähnisch H, Bachmann MP, Rieber EP, Schetelig J, Ehninger G, Schmitz M. Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T-cell-depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia. Blood. 2011;117:7174-7184.
67. Stamova S, Cartellieri M, Feldmann A, Bippes CC, Bartsch H, Wehner R, Schmitz M, von Bonin M, Bornhäuser M, Ehninger G, Rieber EP, Bachmann M. Simultaneous engagement of activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells. Leukemia. 2011;25:1053-1056.
66. Wehner R, Dietze K, Bachmann M, Schmitz M. The bi-directional crosstalk between human dendritic cells and natural killer cells. J Innate Immun. 2011;3:258-263.
65. Feldmann A, Stamova S, Bippes CC, Bartsch H, Wehner R, Schmitz M, Temme A, Cartellieri M, Bachmann M. Retargeting of T cells to prostate stem cell antigen expressing tumor cells: comparison of different antibody formats. Prostate. 2011;71:998-1011.
64. Bippes CC, Feldmann A, Stamova S, Cartellieri M, Schwarzer A, Wehner R, Schmitz M, Rieber EP, Zhao S, Schäkel K, Temme A, Scofield RH, Kurien BT, Bartsch H, Bachmann MP. A novel modular antigen delivery system for immuno targeting ofhuman 6-sulfo LacNAc-positive blood dendritic cells. PLoS One. 2011;e16315.
63. Hänsel A, Günther C, Ingwersen J, Starke J, Schmitz M, Bachmann M, Meurer M, Rieber EP, Schäkel K. Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong Th17/Th1 T-cell responses. J Allergy Clin Immunol. 2011;127:787-794.
62. Maiwald S, Wehner R, Schmitz M, Bornhäuser M, Loeb S, Wassmuth R. IDO1 and IDO2 gene expression analysis by quantitative PCR. Tissue Antigens. 2011;77:136-42.
61. Röllig C, Schmidt C, Bornhäuser M, Ehninger G, Schmitz M, Auffermann-Gretzinger S. Induction of cellular immune responses in patients with stage I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells. J Immunother. 2011;34:100-106.
60. Jähnisch H, Füssel S, Kiessling A, Wehner R, Zastrow S, Bachmann M, Rieber EP, Wirth MP, Schmitz M. Dendritic cell-based immunotherapy for prostate cancer. Clin Dev Immunol. 2010 ;2010:517493.
59. Wehner R, Schumacher P, Bornhäuser M, Ehninger G, Schäkel K, Bachmann M, Schmitz M. Acute myeloid leukemia cells fail to activate human dendritic cells: a potential mechanism of immune evasion. Leukemia. 2010:24:1965-1967.
58. Seeger EM, Thuma M, Fernandez-Moreira E, Jacobs E, Schmitz M, Helbig JH. Soluble liposaccharide shed by Legionella pneumophila arrests phagosome maturation in amoeba and monocytic host cells. FEMS Microbiol Lett. 2010;307:113-119.
57. Cartellieri M, Bachmann M, Feldmann A, Bippes C, Stamova S, Wehner R, Temme A, Schmitz M. Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J Biomed Biotechnol. 2010;2010:956304.
56. Zhao S, Wehner R, Bornhäuser M, Wassmuth R, Bachmann M, Schmitz M. Immunomodulatory properties of mesenchymal stromal cells and their therapeutic consequences for immune-mediated disorders. Stem Cells Dev. 2010;19:607-614.
55. Wehner R, Wehrum D, Bornhäuser M, Zhao S, Schäkel K, Bachmann MP, Platzbecker U, Ehninger G, Rieber EP, Schmitz M. Mesenchymal stem cells efficiently inhibit the proinflammatory properties of 6-sulfo LacNAc dendritic cells. Haematologica. 2009;94:1151-1156.
54. Canzler U, Bartsch H, Ulitzsch S, Kurien BT, Dorri Y, Scofield RH, Grossmann K, Lehmann W, Pilarsky C, Denz A, Grützmann R, Conrad K, Schmitz M, Rieber EP, Distler W, Bachmann MP. Detection of autoantibodies to tumor-associated antigens in sera of patients with systemic autoimmunity using novel protein microblot array. Scan J Immunol. 2009;69:563-569.
53. Gerner M, Hölig K, Wehner R, Zhao S, Schäkel K, Bachmann MP, Rieber EP, Bornhäuser M, Schmitz M. Extracorporeal photopheresis efficiently impairs the proinflammatory capacity of human 6-sulfo LacNAc dendritic cells. Transplantation. 2009;87:1134-1139.
52. Von Bonin M, Stölzel F, Goedecke A, Richter K, Wuschek N, Hölig K, Platzbecker U, Illmer T, Schaich M, Schetelig J, Kiani A, Ordemann R, Ehninger G, Schmitz M, Bornhäuser M. Treatment of refractory acute GvHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant. 2009;43:245-251.
51. Wehner R, Löbel B, Bornhäuser M, Schäkel K, Cartellieri M, Bachmann M, Rieber EP, Schmitz M. Reciprocal activating interaction between 6-sulfo LacNAc+ dendritic cells and NK cells. Int J Cancer. 2009;124:358-366.
50. Schulze A, Schirutschke H, Oelschlägel U, Schmitz M, Füssel M, Wassmuth R, Ehninger G, Bornhäuser M, Platzbecker U. Altered phenotype of natural killer cell subsets after haploidentical stem cell transplantation. Exp Hematol. 2008;36:378-389.
49. Kiessling A, Füssel S, Wehner R, Bachmann M, Wirth MP, Rieber EP, Schmitz M. Advances in specific immunotherapy for prostate cancer. Eur Urol. 2008;53:694-708.
48. Krause M, Schmitz M, Noessner E, Skrablin P, Wehner R, Rieber EP, Baumann M. Adoptive transfer of cytotoxic T cells for treatment of residual disease after irradiation. Int J Radiat Biol. 2007;83:827-836.
47. Straube C, Wehner R, Wendisch M, Bornhäuser M, Bachmann M, Rieber EP, Schmitz M. Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells. Leukemia. 2007;21:1464-1471.
46. Piesche M, Hildebrandt Y, Zettl F, Chapuy B, Schmitz M, Wulf G, Trümper L, Schroers R. Identification of a promiscuous HLA-DR-restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin. Hum Immunol. 2007;68:572-576.
45. Morgenroth A, Cartellieri M, Schmitz M, Günes S, Weigle B, Bachmann M, Abken H, Rieber EP, Temme A. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T cells. Prostate. 2007;67:1121-1131.
44. Schmitz M, Temme A, Senner V, Ebner E, Schwind S, Stevanovic S, Wehner R, Schackert G, Schackert HK, Fussel M, Bachmann M, Rieber EP, Weigle B. Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy. Br J Cancer. 2007;96:1293-1301.
43. Temme A, Rodriguez JA, Hendruschk S, Günes S, Weigle B, Schäkel K, Schmitz M, Bachmann M, Schackert G, Rieber EP. Nuclear localization of survivin renders HeLa tumor cells more sensitive to apoptosis by induction of p53 and Bax. Cancer Lett. 2007;250:177-193.
42. Söling A, Plugge EM, Schmitz M, Weigle B, Jacob R, Illert J, Holzhausen HJ, Rainov NG. Autoantibodies to the inhibitor of apoptosis protein survivin in patients with brain tumors. Int J Oncol. 2007;30:123-128.
41. Schmitz M, Wehner R, Stevanovic S, Kiessling A, Rieger MA, Temme A, Bachmann M, Rieber EP, Weigle B. Identification of a naturally processed T cell epitope derived from the glioma-associated protein SOX11. Cancer Lett. 2007;245:331-336.
40. Bornhäuser M, Thiede C, Babatz J, Schetelig J, Illmer T, Kiani A, Platzbecker U, Herr W, Rieber EP, Ehninger G, Schmitz M. Infusion of bcr/abl peptide-reactive donor T cells to achieve molecular remission of chronic myeloid leukemia after CD34+ selected allogeneic hematopoietic cell transplantation. Leukemia. 2006;20:2055-2057.
39. Wehner R, Wendisch M, Schäkel K, Bornhäuser M, Platzbecker U, Mohr B, Temme A, Bachmann M, Rieber EP, Schmitz M. Imatinib mesylate does not impair the immunogenicity of human myeloid blood dendritic cells. Leukemia. 2006;20:1629-1632.
38. Bachmann MP, Bartsch H, Gross JK, Maier SM, Gross TF, Workman JL, James JA, Farris AD, Jung B, Franke C, Conrad K, Schmitz M, Büttner C, Buyon JP, Semsei I, Harley JB, Rieber EP. Autoimmunity as a result of escape from RNA surveillance. J Immunol. 2006;177;1698-1707.
37. Fuessel S, Meye A, Schmitz M, Zastrow S, Linné C, Richter K, Löbel B, Hakenberg OW, Hoelig K, Rieber EP, Wirth MP. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial. Prostate. 2006;66:811-821.
36. Kuhla B, Boeck K, Lüth HJ, Schmidt A, Weigle B, Schmitz M, Ogunlade V, Münch G, Arendt T. Age-dependent changes of glyoxalase I expression in human brain. Neurobiol Aging. 2006;27:815-822.
35. Babatz J, Röllig C, Löbel B, Folprecht G, Haack M, Günther H, Köhne CH, Ehninger G, Schmitz M, Bornhäuser M. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer Immunol Immunother. 2006;55:268-276.
34. Schmitz M, Kiessling A, Weigle B, Fuessel S, Meye A, Wehner R, Temme A, Bachmann M, Wirth MP, Rieber EP. T cell-based strategies for immunotherapy of prostate cancer. Cancer Therapy. 2005;3:565-578.
33. Schetelig J, Kiani A, Schmitz M, Ehninger G, Bornhäuser M. T cell-mediated graft-versus-leukemia reactions after allogeneic stem cell transplantation. Cancer Immunol Immunother. 2005;54:1043-1058.
32. Kiessling A, Weigle B, Fuessel S, Ebner R, Meye A, Rieger MA, Schmitz M, Temme A, Bachmann M, Wirth MP, Rieber EP. D-TMPP: a novel androgen-regulated gene preferentially expressed in prostate and prostate cancer that is the first characterized member of a eukaryotic gene family. Prostate. 2005;64:387-400.
31. Schmitz M, Zhao S, Deuse Y, Schäkel K, Wehner R, Wöhner H, Hölig K, Wienforth F, Kiessling A, Bornhäuser M, Temme A, Rieger MA, Weigle B, Bachmann M, Rieber EP. Tumoricidal potential of native blood dendritic cells: direct tumor cell killing and activation of NK cell-mediated cytotoxicity. J Immunol. 2005;174:4127-4134.
30. Temme A, Herzig E, Weigle B, Morgenroth A, Schmitz M, Kiessling A, Rieger MA, Schackert HK, Rieber EP. Inhibition of malignant glioma cell growth by a survivin mutant retrovirus. Hum Gene Ther. 2005;16:209-222.
29. Meyer RG, Britten CM, Siepmann U, Petzold B, Sagban TA, Lehr HA, Weigle B, Schmitz M, Mateo L, Schmidt B, Bernhard H, Jakob T, Hein R, Schuler G, Schuler-Thurner B, Wagner SN, Drexler I, Sutter G, Arndtz N, Chaplin P, Metz J, Enk A, Huber C, Wölfel T. A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr). Cancer Immunol Immunother. 2005;54:453-467.
28. Temme A, Diestelkoetter-Bachert P, Schmitz M, Morgenroth A, Weigle B, Rieger MA, Kiessling A, Rieber EP. Increased p21ras activity in human fibroblasts transduced with survivin enhances cell proliferation. Biochem Biophys Res Commun. 2005;327:765-773.
27. Weigle B, Ebner R, Temme A, Schwind S, Schmitz M, Kiessling A, Rieger MA, Schackert G, Schackert HK, Rieber EP. Highly specific overexpression of the transcription factor SOX11 in human malignant gliomas. Oncol Rep. 2005;13:139-144.
26. Weigle B, Fuessel S, Ebner R, Temme A, Schmitz M, Schwind S, Kiessling A, Rieger MA, Meye A, Bachmann M, Wirth MP, Rieber EP. D-GPCR: a novel putative G protein-coupled receptor overexpressed in prostate cancer and prostate. Biochem Biophys Res Commun. 2004;322:239-249.
25. Rieger MA, Ebner R, Bell DR, Kiessling A, Rohayem J, Schmitz M, Temme A, Rieber EP, Weigle B. Identification of a novel mammary-restricted cytochrome P450, CYP4Z1, with overexpression in breast carcinoma. Cancer Res. 2004;64:2357-2364.
24. Weigle B, Kiessling A, Ebner R, Fuessel S, Temme A, Meye A, Schmitz M, Rieger MA, Ockert D, Wirth MP, Rieber EP. D-PCa-2: a novel transcript highly overexpressed in human prostate and prostate cancer. Int J Cancer. 2004;109:882-892.
23. Kiessling A, Stevanovic S, Füssel S, Weigle B, Rieger MA, Temme A, Rieber EP, Schmitz M. Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein prostein. Br J Cancer. 2004;90:1034-1040.
22. Babatz J, Röllig C, Oelschlägel U, Zhao S, Ehninger G, Schmitz M, Bornhäuser M. Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a phase I study. J Hematother Stem Cell Res. 2003;12:515-523.
21. Kiessling A, Füssel S, Schmitz M, Stevanovic S, Meye A, Weigle B, Klenk U, Wirth MP, Rieber EP. Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein trp-p8. Prostate. 2003;56:270-279.
20. Zeis M, Siegel S, Wagner A, Schmitz M, Marget M, Kühl-Burmeister R, Adamzik I, Kabelitz D, Dreger P, Schmitz N, Heiser A. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin RNA-transfected dendritic cells. J Immunol. 2003;170:5391-5397.
19. Fuessel S, Sickert D, Meye A, Klenk U, Schmidt U, Schmitz M, Rost AK, Weigle B, Kiessling A, Wirth MP. Multiple tumor marker analyses (PSA, hK2, PSCA, trp p8) in primary prostate cancers using quantitative RT-PCR. Int J Oncol. 2003;23:221-228.
18. Temme A, Morgenroth A, Schmitz M, Weigle B, Rohayem J, Lindemann D, Füssel M, Ehninger G, Rieber EP. Efficient transduction and long-term retroviral expression of the melanoma-associated tumor antigen tyrosinase in CD34+ cord blood-derived dendritic cells. Gene Ther. 2002;9:1551-1560.
17. Kiessling A, Schmitz M, Stevanovic S, Weigle B, Hölig K, Füssel M, Füssel S, Meye A, Wirth MP, Rieber EP. Prostate stem cell antigen: identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients. Int J Cancer. 2002;102:390-397.
16. Schmitz M, Bornhäuser M, Ockert D, Rieber EP. Cancer immunotherapy: novel strategies and clinical experiences. Trends Immunol. 2002;23:428-429.
15. Schmitz M, Zhao S, Schäkel K, Bornhäuser M, Ockert D, Rieber EP. Native human blood dendritic cells as potent effectors in antibody-dependent cellular cytotoxicity. Blood. 2002;100:1502-1504.
14. Schmitz M, Rohayem J, Paul R, Weigle B, Stein A, Rieber EP. Quantification of antigen-reactive T cells by a modified ELISPOT assay based on freshly isolated blood dendritic cells. J Clin Lab Anal. 2002;16:30-36.
13. Kappler M, Köhler T, Kampf C, Diestelkötter P, Würl P, Schmitz M, Bartel F, Lautenschläger C, Rieber EP, Schmidt H, Bache M, Taubert H, Meye A. Increased survivin transcript levels: an independent negative predictor of survival in soft tissue sarcoma patients. Int J Cancer. 2001;95:360-363.
12. Schmitz M, Bornhäuser M, Ockert D, Rieber EP. Third international Dresden symposium on immunotherapy of cancer. Cancer Res. 2001;61:3524-3528.
11. Thiede C, Wündisch T, Alpen B, Neubauer B, Morgner A, Schmitz M, Ehninger G, Stolte M, Bayerdörffer E, Neubauer A. Long-term persistence of monoclonal B-cells after cure of Helicobacter pylori infection and complete histologic remission in gastric mucosa- associated lymphoid tissue B cell lymphoma. J Clin Oncol. 2001;19:1600-1609.
10. Schmitz-M, Diestelkoetter P, Weigle B, Schmachtenberg F, Stevanovic S, Ockert D, Rammensee HG, Rieber EP. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res. 2000;60:4845-4849.
9. Rohayem J, Diestelkoetter P, Weigle B, Oehmichen A, Schmitz M, Mehlhorn J, Conrad K, Rieber EP. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res. 2000;60:1815-1817.
8. Köhler T, Plettig R, Wetzstein W, Schmitz M, Ritter M, Mohr B, Schaekel U, Ehninger G, Bornhäuser M. Cytokine-driven differentiation of blasts from patients with acute myelogenous and lymhoblastic leukemia into dendritic cells. Stem Cells. 2000;18:139-147.
7. Kniep B, Schäkel K, Nimtz M, Schwartz-Albiez R, Schmitz M, Northoff H, Vilella R, Gramatzki M, Rieber EP. Differential expression of alpha 2-6 sialylated polylactosamine structures by human B and T cells. Glycobiology. 1999;9:399-406.
6. Ockert D, Schmitz M, Hampl M, Rieber EP. Advances in cancer immunotherapy. Immunol Today. 1999;20:63-65.
5. Drexler I, Antunes E, Schmitz M, Wölfel T, Huber C, Erfle V, Rieber P, Theobald M, Sutter G. Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo. Cancer Res. 1999;59:4955-4963.
4. Schäkel K, Mayer E, Federle C, Schmitz M, Riethmüller G, Rieber EP. A novel dendritic cell population in human blood: one-step immunomagnetic isolation by a specific mAb (M-DC8) and in vitro priming of cytotoxic T lymphocytes. Eur J Immunol. 1998;28:4084-4093.
3. Orth T, Mayet WJ, Deister H, Chang S, Schmitz M, Bachmann M. Analysis of epitope spreading over an eleven-year period in a patient with systemic lupus erythematosus. Scand J Rheumatol. 1998;27:461-464.
2. Bachmann M, Deister H, Pautz A, Laubinger J, Schmitz M, Falke D, Podlech J, Grölz D. The human autoantigen La/SS-B accelerates herpes simplex virus type 1 replication in transfected mouse 3T3 cells. Clin Exp Immunol. 1998;112:482-489.
1. Schmitz M, Bachmann M, Laubinger J, Thijssen JP, Pruijn GJ. Characterization of murine monoclonal antibodies against the Ro52 autoantigen. Clin Exp Immunol. 1997;110:53-62.